Dovitinib enhances temozolomide efficacy in glioblastoma cells

The multikinase inhibitor and FDA‐approved drug dovitinib (Dov) crosses the blood–brain barrier and was recently used as single drug application in clinical trials for GB patients with recurrent disease. The Dov‐mediated molecular mechanisms in GB cells are unknown. We used GB patient cells and cell...

Full description

Saved in:
Bibliographic Details
Published in:Mol Oncol
Main Authors: Thanasupawat, Thatchawan, Natarajan, Suchitra, Rommel, Amy, Glogowska, Aleksandra, Bergen, Hugo, Krcek, Jerry, Pitz, Marshall, Beiko, Jason, Krawitz, Sherry, Verma, Inder M., Ghavami, Saeid, Klonisch, Thomas, Hombach‐Klonisch, Sabine
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2017
Subjects:
Research Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5537714/
https://ncbi.nlm.nih.gov/pubmed/28500786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12076
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items